United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sovereign medical ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aristo pharma ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rivopharm (uk) ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - vardenafil hydrochloride trihydrate - oral tablet - 20mg

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - vardenafil hydrochloride trihydrate - orodispersible tablet - 10 milligram(s) - drugs used in erectile dysfunction; vardenafil

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil 20 mg - levitra ® is indicated for the treatment of erectile dysfunction. administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology ( 12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including levitra, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of levitra for the safe administration of nitrates or nitric oxide donors has not been determined. do not use levitra in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including levitra may potentiate the hypotensive effects of gc stimulators. levitra is not indicated for use in women. there are no studies of levitra use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that recei